Document:

Order to ship to Hemp, Inc.Exhibit 10.5

 

	 	Proposal & Product Description

PO Box 353 Bloomfield, IN 47424 | Phone 812-762-4400

www.nuaxontech.com

 

	Proposal Heading

 

 

Date prepared: March 16, 2017

 

Company: Freedom Leaf, Inc.

Contact: Clifford J Perry or Raymond P Medeiros

Address: 3571 East Sunset Road, Suite 420, Las Vegas, NV
89120

Phone: CJP: 954-895-3316; RPM 415-601-1974

Email: cliff@freedomleaf.com; ray@freedomleaf.com

 

	Basic Description of Proposed Equipment

 

	Model number: 5L1602FA

System description: Closed loop system for transport of CO2
from gaseous state to liquid state to supercritical fluid state.

Height of Unit: 8 feet

Approximate floor space required: 8’ x 5’

Extraction vessel size: 5 Liter

Number of extraction vessels: 2

	Separator vessel size: 2.5 Liter

Number of separator vessels: 2

Number of water separators: 1

Flow Rate: 30 Liters per hour

Lead time until shipment: 12 weeks

Estimated Ship time: 5 weeks

Estimated time for set up: 3 days

 

	System Features and Scope of
    Work

 

	1.		System designed to meet cGMP.

	2.		Extraction vessel designed with safety closures and special seals suitable for CO2
duty and quick closures for separator vessels.

	3.		Modular steel frame for mounting of extraction vessels and all peripherals including
controls.

	4.		Maximum operating pressure for extractors is 350 bar (5076 psi) and maximum temperature
is 55C.

	5.		Maximum operating pressure for separator #1 ‎is 130 bar (1885 psi) and 70 bar
(1015 psi) for separator #2.

	6.		Additional water separator to trap the higher notes, and the most elusive terpenes.

	7.		All contact parts are SS 316, noncontact parts are SS 306 and the supporting structure
is SS 306 or MS with epoxy coat.

	8.		Easy to use SCADA system with semiautomatic and manual mode options.

	9.		System logs all data electronically for analysis.

	10.		System has remote troubleshooting capabilities via a standard internet connection.

	11.		Optional smart phone app for management and control oversight.

	12.		Recycling of CO2 for environmental and fiscal conservation.

	13.		Two stage safety with interlocked electronic controls and second stage mechanical
safety.

	14.		High technology pressure regulation system consisting of servo controlled automated
back pressure regulator.

	15.		Specially developed motorized and metering CO2 pump with controls for variable
pressure and flow rate control.

 

 

 

Proposal good for 15 days from date of proposal

    	 	1	 

     

    

 

	 	Proposal & Product Description

PO Box 353 Bloomfield, IN 47424 | Phone 812-762-4400

www.nuaxontech.com

 

This is a complete system with the exclusions noted in this proposal. On site erection
and commissioning for an extra charge. We will assign a skilled technician for erecting and training of plant operations.

 

All rigging and material movement will be done
by you under our supervision. Warranty will be voided on any work done without our project manager onsite.

 

	Exclusions
and Client Responsibilities

 

	1.		U stamp pressure vessel certification, extra if required. Optional, and will increase
the cost by 5 to 10%. Purchaser must verify local requirements.

	2.		Any civil work if required must be completed prior to scheduled installation.

	3.		Client must have an indoor space prepared of great enough size to accommodate the
equipment including a concrete floor sufficient to hold the weight of the equipment, and a ceiling high enough to accommodate
it.

	4.		Provision for utilities such as electrical power, water, and heater connections to
the plant at specific location.

	5.		Client must have a licensed refrigeration contractor on site to install and commission
the required condensing units as per local regulation.

	6.		Air compressor (2 HP) for pneumatic operations and piping for air flow as required
at site.

	7.		Installation team will not be scheduled until client can provide documentation and
photographic evidence that the compressor is installed and operational.

	8.		Three phase power 230 V/ 60 Hz connection is required, and client must have a licensed
electrician on site at the time of commissioning. If a permanent three phase power supply is not provided with due protection
for the extraction unit’s electrical components, then the warranty for the extraction unit will be considered null and void.

	9.		Adequate CO2 supply (minimum of 200 Liters) at 60 bar to be provided by the client
in to the storage tank for the extraction plant. This must be on hand prior to the arrival of the installation team for commissioning.
CO2 must be committed for testing only and might not be preserved for use after set up and testing, this is at the client’s
expense.

	10.		Any work outside the battery limits of the plant that is inlet of the CO2 storage
tank and exhaust from the separator will be the sole responsibility of the client.

	11.		Installation team will be working weekends and holidays during the installation and
commissioning, client must provide access, personnel and required resources for every day during the scheduled installation period.

	12.		The equipment is designed as an indoor unit and requires a temperature controlled
area for storage and operation. The allowable temperature range for operating the equipment is between 18C (65F) to 30C (85F).

	13.		A minimum of 2 batches of raw material will be required for proper commissioning and
fine tuning of the equipment. The client is solely responsible for procuring material that has been properly dried and ground
as required by the commissioning team. Raw material must be committed for testing only and might not be preserved for use after
set up and testing, this is at the client’s expense.

	14.		In the event that installation is delayed beyond 90 days after the equipment is delivered
to the client’s ship to address, all additional costs due to storage related issues will be sole responsibility of the client.
This includes but is not limited to, seals, pump parts, rusted parts, weathered parts, expedited shipping for said parts, software
resets, and extended housing, transportation and food cost for a prolonged commissioning period.

 

 

Proposal good for 15 days from date of proposal

    	 	2	 

     

    

 

	 	Proposal & Product Description

PO Box 353 Bloomfield, IN 47424 | Phone 812-762-4400

www.nuaxontech.com

 

	Warranty and Terms

 

NuAxon Bioscience, Inc. warrants that this equipment will be free from defect in material
and workmanship for a period of 12 months from date of powered startup or 18 months from date of delivery whichever is less.

 

Warranty does not apply to normal wear and
tear, consumables, misuse and equipment that is not maintained as per schedule of maintenance. Warranty will not cover explosion,
erosion and effects of electro-chemical corrosion and such areas of use which are beyond the control of the manufacturer. Any defects
and deficiencies will be rectified / replaced by NuAxon Bioscience, Inc. at their option and judgment. Warranty will be voided
on any work done without our project manager onsite.

 

Ongoing service support other than warranted
issues, is available but is contracted separately from this document. Likewise routine spares and supplies required for normal
maintenance as well as normal wear and tear are quoted and supplied separately.

 

NuAxon accepts wire transfers, bank check (10
business days to clear) or credit card (additional 2.5% fee) for payment. Down payment required with purchase order to begin work
on the equipment production.

 

Down payment – 50% due prior to the start
of production.

2nd Instalment – 25% due upon
approval of the construction drawings, not later than 60 days after beginning the project.

Final instalment – Balance due within
7 days of notification that unit is ready for shipping from the factory.

Payment terms are based on total invoice amount.

 

All drawings, technical data, product information
and operational information are the sole property of NuAxon and may not be shared, distributed, duplicated or transmitted in any
form to any party outside the client company without the express written consent of NuAxon.

 

 

Proposal good for 15 days from date of proposal

    	 	3	 

     

    

 

	 	Proposal & Product Description

PO Box 353 Bloomfield, IN 47424 | Phone 812-762-4400

www.nuaxontech.com

 

Order to ship to Hemp, Inc.

 

 

	Pricing

 

	Upfront Costs
	Plant complete after deducting 7% commission	$195,300
	Packing 	$10,600
	Installation	$10,000
	Total Due Upfront	$215,900
	 	 
	Plus Other Associated Costs at Actual
	Shipping cost estimated (by sea)	$6,000
	Shipping cost estimated (by air)	$10,000
	Customs Duty estimated 	$5,400
	Smartphone App	$5,000

 

 

This offer accepted by the undersigned will be considered a purchase
order and will be fully executed when accompanied by the required down payment.

 

Order to fulfill Hemp, Inc. Order received On February 21, 2017

 

Freedom Leaf, Inc.

 

Name: Raymond P Medeiros

Please Print

 

	Title: Vice President Business Development    	 Date:  March 15, 2017	 
	Company
    Position	 MM
    / DD / YY 	

 

 

Signature               /s/
Raymond P Medeiros                 

 

 

Proposal good for 15 days from date of proposal

 

    	 	4Exhibit

Exhibit 10.2

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

This Amended and Restated Employment Agreement (the “Agreement”) is made as of October 19, 2015 (the “Effective Date”), between Patheon Pharmaceutical Services Inc.  (the “Company”) and Francisco Negron (the “Executive”).

A. The Company is a subsidiary of Patheon Holdings Cooperatief U.A., whose name is expected to change to Patheon N.V. (“Patheon”).  Patheon is the corporate parent of a group of businesses, including DPx Holdings B.V. and the subsidiaries thereunder, engaged in the provision of commercial manufacturing and development services (pharmaceuticals and fine chemicals) and related services.  As used herein, “Patheon Group” means Patheon and any entity controlled directly or indirectly by Patheon or its successor in interest.

B. Each of the Company and the Executive are parties to that certain Employment Agreement, dated as of October 15, 2009 and as amended from time to time (as amended as of the date hereof, the “Prior Employment Agreement”).

C. The Company wishes to continue to employ the Executive, and the Executive wishes to continue to be employed by the Company, pursuant to the terms and subject to the conditions set forth in this Agreement, in the position described herein. 

D. The Company and the Executive wish to amend and restate the Prior Employment Agreement in its entirety by entering into this Agreement setting forth the rights and obligations of each of them with respect to the employment of the Executive.

E. Notwithstanding any provisions related to termination of employment or this Agreement, employment is “at will”, meaning that either the Company or the Executive can terminate the employment relationship or this Agreement at any time subject only to contractual payments agreed to herein as may be applicable.    

F. The Company and the Executive agree that the terms, provisions and mutual covenants of this Agreement suffice as adequate consideration for their mutual promises made in this Agreement.

NOW, THEREFORE, the parties agree as follows:

ARTICLE 1
DEFINITIONS

Definitions.  In this Agreement, including Schedule A hereto, unless the context otherwise requires, the following terms shall have the following meanings, respectively: 

		
	a.
	“Board of Directors” means, prior to any IPO, the Board of Directors of JLL/Delta Patheon Holdings, L.P (the “Partnership”) and upon and after any IPO, the Board of Directors of the issuer of the publicly traded equity securities resulting from such IPO.

		
	b.
	“Cause” means the determination, in good faith, by the Company, after notice to the Executive that one or more of the following events has occurred:  (i) the Executive has failed to perform his material duties, and, if curable, such failure has not been cured after a period of thirty (30) days’ notice from the Company; (ii) any intentional or negligent act by the Executive having the potential or actual effect of injuring the interests, business, or reputation of any member of the Patheon Group in any material respect; (iii) the Executive’s commission of any felony (including entry of a nolo contendere or other plea not contesting charges); (iv) any misappropriation or embezzlement of the property of any member of the Patheon Group; (v) a material breach of any provision of this Agreement by the Executive, which breach, if curable, remains uncured for a period of thirty (30) days after receipt by the Executive of notice from the Company of such breach; or (vi) a material breach of Company Policy by the Executive, including but not limited to violation of policies and procedures regarding Patheon Group information as described in Schedule A hereto, which breach, if curable, remains uncured for a period of thirty (30) days after receipt by the Executive of notice from the Company of such breach.

		
	c.
	“Change in Control” means, prior to any IPO, the occurrence of any of the following events:

		
	(i)
	the sale of all or substantially all of the assets of the Partnership to any Person (or group of Persons acting in concert), other than to (A) the Initial Investors or their respective Affiliates or (B) any employee benefit plan (or trust forming a part thereof) maintained by the Partnership or another Person of which a majority of its voting power or other Equity Securities is owned, directly or indirectly, by the Partnership; or 

		
	(ii)
	a merger, consolidation, recapitalization or other reorganization by the Partnership, or a sale or disposition by the Partners to any Person (or group of Persons acting in concert) of Equity Securities or voting power, in each case, that results in any Person (or group of Persons acting in concert) (other than (A) the Initial Investors or their respective Affiliates or (B) any employee benefit plan (or trust forming a part thereof) maintained by the Partnership or another Person of which a majority of its voting power or other Equity Securities is owned, directly or indirectly, by the Partnership) owning more than 50% of the outstanding Equity Securities or voting power of the Partnership (or any resulting company after a merger, consolidation or other reorganization).

The terms used but not defined in this Section 1(c) have the meanings set forth in the Fourth Amended and Restated Agreement of Exempted Limited Partnership of JLL/Delta Patheon Holdings, L.P., as amended (as the same may be amended, modified or restated from time to time, the “Partnership Agreement”).

Upon and after an IPO, “Change in Control” shall have the meaning ascribed to such term in the omnibus equity incentive plan and any successor thereto adopted by the Company or any of its affiliates in connection with or following the IPO.

		
	d.
	“Code” means the Internal Revenue Code of 1986, as amended.

		
	e.
	“Compensation Committee” shall mean the Compensation Committee and Human Resources Committee of the Board of Directors.

		
	f.
	“Disability” means the Executive’s inability to substantially fulfill his duties on behalf of the Company such that he or she has been approved for long-term disability benefits pursuant to the Company’s long-term disability plan interpreted in a manner consistent with Section 1.409A-3(i)(4) of the Treasury Regulations.

		
	g.
	“Excluded Termination”  means a termination of the Employee’s employment with the Company:

		
	(a)
	by the Company or any successor company for Cause;

		
	(b)
	by the Executive other than for Good Reason; or

		
	(c)
	as a result of the Disability, death or retirement of the Executive.

		
	h.
	“Good Reason” means the occurrence of any of the following events without the consent of the Executive: (i) a material reduction of the Executive’s duties or responsibilities or the assignment to the Executive of duties or responsibilities materially inconsistent with the Executive's position; or (ii) a material breach by the Company of this Agreement, which breach remains uncured for a period of thirty (30) days after receipt by the Company of written notice from Executive.  A termination of the Executive's employment by Executive shall not be deemed to be for Good Reason unless (i) the Executive gives notice to the Company of the existence of the event or condition constituting Good Reason within thirty (30) days after such event or condition initially occurs or exists, (ii) the Company fails to cure such event or condition within thirty (30) days after receiving such notice, and (iii) the Executive's “separation from service” within the meaning of Section 409A of the Code occurs not later than ninety (90) days after such event or condition initially occurs or exists.

		
	i.
	“IPO” shall have the meaning ascribed to such term in the Partnership Agreement.

ARTICLE 2
EFFECTIVE DATE; TERMS OF EMPLOYMENT

2.1        Term

The Company hereby agrees to continue to employ the Executive, and the Executive hereby agrees to continue to be employed by the Company pursuant to the terms and subject to the conditions of this Agreement (including, without limitation, Article 6 and Schedule A), commencing on the Effective Date. The Executive’s employment with the Company will be “at will,” meaning that either the Executive or the Company will be entitled to terminate the Executive’s employment at any time and for any reason, with or without Cause. Any contrary representations which may have been made to the Executive are superseded by this Agreement. This is the full and complete agreement between the Executive and the Company on this term. Although the Executive’s job duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the 

“at will” nature of the Executive’s employment may only be changed in an express written agreement signed by the Executive and a duly authorized officer of the Company.

		
	2.2
	Position and Duties

The Executive shall be employed by the Company and shall serve as President, Drug Product Services, with such authority, duties and responsibilities as are commensurate with such position, reporting to the Chief Executive Officer.

In addition, the Executive will be a member of the Patheon Group’s Executive Committee and will continue to be an officer of Patheon and of any member company of the Patheon Group, as may be requested.

The location of the Executive’s employment will be the Framingham offices of the Company, located at 111 Speen Street, Suite 550 Framingham, MA  01701, or such other location where the principal executive offices may be relocated from time to time by the Company. 

2.3    Standards of Performance and Time Commitments

The Executive will, at all times, faithfully, industriously, and to the best of his ability, experience and talents, perform all of the duties required of and from him or her pursuant to the terms of this Agreement.  During the Executive’s employment, the Executive shall devote substantially all of his working time and attention to his duties with the Patheon Group, shall have and comply with a duty of loyalty to the Company and the Patheon Group, and shall render no material business services to any other person or company; provided, however, it shall not be a violation of this Agreement for the Executive, subject to the requirements of Article 6, to spend reasonable amounts of time to manage his personal, financial and legal affairs.    

ARTICLE 3
COMPENSATION AND BENEFITS
3.1    Base Salary

The Company shall pay the Executive an annualized base salary ("Annual Base Salary") of U.S. $425,000, retroactive to September 1, 2015 and payable pursuant to the Company’s regular payroll practices for its executives in effect at the time, subject to applicable withholdings and deductions.  The Annual Base Salary shall be reviewed by the Chief Executive Officer and the Compensation Committee, for increase only, at such time as the salaries of other senior executives of the Company are reviewed generally. 

3.2    Executive Short-Term Incentive Award 

The Executive shall be eligible to participate in an annual performance incentive plan under terms and conditions no less favorable than those applicable to other senior executives of the Company; provided that the Executive's target short-term incentive shall not be less than sixty percent (60%) of his Annual Base Salary, effective November 1, 2015. Executive’s target short-term incentive for the Company’s fiscal year ended October 31, 2015 shall remain forty-five percent (45%) of his Annual Base Salary.  For purposes of this Section 3.2, Annual Base Salary shall mean the Executive’s eligible earnings as provided in the applicable short-term incentive plan.  The Executive's payment under the annual performance incentive plan shall be based on meeting predetermined personal objectives as assessed by the Chief Executive Officer in his sole discretion, and the Company’s financial performance as assessed by the Chief Financial Officer and the Compensation Committee.  The personal objectives will normally be set by the Chief Executive Officer. The annual performance bonus, if any, will be paid to the Executive by the Company in the same manner and payment period generally applicable under the annual performance incentive plan and state law, but in no event later than two and a half months after the later of (i) the end of the applicable performance period, or (ii) the end of the calendar year in which the performance period ends. Nothing contained in this Section 3.2 will guarantee the Executive any specific amount of incentive compensation, or prevent the Chief Executive Officer or Compensation Committee from establishing or modifying performance goals and compensation targets applicable only to the Executive.  The decision as to whether to have a short-term incentive plan or to fund such a plan, as well as the decision as to whether Executive shall receive a short-term incentive payment, or any short-term incentive is at the Company’s sole discretion.  Any bonus or short-term incentive payment is not “wages” for labor performed. 

3.3    Equity Incentive Plan

Executive will be eligible to participate in the JLL/DELTA PATHEON HOLDINGS, L.P. 2014 Equity Incentive Plan (the “MEIP”) and, prior to any IPO, will be eligible to be awarded Management Units from time to time in accordance with the terms of the MEIP, the applicable Management Unit Award Agreement, and all related documents (collectively, the “MEIP Related Documents”).
    

		
	(a)
	Subject to approval of the Compensation Committee at a meeting following the Effective Date, Executive will be awarded 1,000 of the Management Units, which shall be granted subject to the MEIP Related Documents.

		
	(b)
	Executive will be required to comply with and be subject to the terms and conditions of the MEIP Related Documents, as amended from time to time.

3.4    Employee Benefits

The Executive will be entitled to participate in all employee healthcare and welfare benefits programs of the Company, in accordance with the then applicable terms, conditions and eligibility requirements of such programs that are offered from time to time to U.S. resident-based employees at the Executive’s level, including medical, dental, life insurance, 401(k) retirement plans and other health benefit programs.    

In addition, the Executive will be entitled to four (4) weeks of vacation time, subject to the Company’s vacation policy, as may be in effect from time to time. 

3.5    Reimbursement of Business Expenses

The Executive shall be reimbursed for all reasonable travel and other out-of-pocket expenses actually and properly incurred by the Executive during the Executive’s employment in connection with carrying out his duties hereunder in accordance with the Company's policies, as may be in effect from time to time.  
3.7    Sarbanes-Oxley Act Loan Prohibition

To the extent that any Company or Patheon Group benefit, program, practice, arrangement or this Agreement would or might otherwise result in the Executive’s receipt of an illegal loan (the “Loan”), the Company shall use commercially reasonable efforts to provide the Executive with a substitute for the Loan that is lawful and of at least equal value to the Executive. If this cannot be done, or if doing so would be significantly more expensive to the Company than making the Loan, the Company need not make the Loan to the Executive or provide any substitute for it.   

		
	3.8
	Clawback Policy 

The Executive agrees that the compensation and benefits provided by the Company under this Agreement or otherwise is subject to recoupment or clawback under any applicable clawback or recoupment policy that is generally applicable to the Company's executives, as may be in effect from time to time, or as required by law.

ARTICLE 4
TERMINATION OF EMPLOYMENT

4.1    Death or Disability

		
	(a)
	The Executive's employment shall be immediately terminated without notice by the Company upon the death of the Executive.  

		
	(b)
	If the Company determines that the Disability of the Executive has occurred during the Executive’s employment, it shall give to the Executive written notice in accordance with Section 7.4 of this Agreement of its intention to terminate the Executive's employment.  In such event, the Executive's employment shall terminate effective on the thirtieth (30th) day after receipt of such notice by the Executive.  

4.2    Cause  

The Executive's employment with the Company may be terminated with or without Cause.  

4.3    Good Reason

The Executive's employment with the Company may be terminated by the Executive with or without Good Reason.  

4.4    Notice of Termination

Any termination by the Company for Cause, or by the Executive for Good Reason, shall be communicated by Notice of Termination to the other party in accordance with Section 7.4.  For purposes of this Agreement, a "Notice of Termination" means a written notice which (a) indicates the specific termination provision in this Agreement relied upon, (b) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive's employment under the provision so indicated and (c) if the Date of Termination (as defined below) is other than the date of receipt of such notice, specifies the termination date (which date shall be not more than 30 days after the giving of such notice).  The failure by the Company or the Executive to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Cause or Good Reason shall not waive any right of the Company or the Executive, respectively, hereunder or preclude the Company or the Executive, respectively, from asserting such fact or circumstance in enforcing the Company's or the Executive’s rights hereunder.

4.5    Date of Termination  

"Date of Termination" means (a) if the Executive's employment is terminated by the Company for Cause, or by the Executive for Good Reason, the date of receipt of the Notice of Termination or any later date specified therein, as the case may be, (b) if the Executive's employment is terminated by the Company other than for Cause or Disability, the Date of Termination shall be the date on which the Company notifies the Executive of such termination and (c) if the Executive's employment is terminated by reason of Disability, the Date of Termination shall be the date thirtieth (30) day after receipt of the written notice given to the Executive by the Company in accordance with Section 4.1(b).  The Company and the Executive shall take all steps necessary (including with regard to any post-termination services by the Executive) to ensure that any termination described in this Section 4.5 constitutes a “separation from service” within the meaning of Section 409A of the Code, and the date on which such separation from service takes place shall be the “Date of Termination.”  

4.6    Resignation from All Positions  

Notwithstanding any other provision of this Agreement, upon the termination of the Executive's employment for any reason, unless otherwise requested by the Board of Directors, the Executive shall immediately resign as of the Date of Termination from all positions that he or she holds or has ever held with the Patheon Group (and with any other entities with respect to which the Patheon Group has requested the Executive to perform services).  The Executive hereby agrees to execute any and all documentation to effectuate such resignations upon request by the Company, but he or she shall be treated for all purposes as having so resigned upon termination of his employment, regardless of when or whether he or she executes any such documentation.

ARTICLE 5
OBLIGATIONS OF THE COMPANY UPON TERMINATION

5.1    Good Reason; Other than for Cause 

If the Company shall terminate the Executive's employment other than for Cause, death or Disability, or if the Executive shall terminate the Executive’s employment for Good Reason: 

		
	(a)
	The Company shall pay, or cause to be paid, to the Executive in a lump sum in cash the sum of: (i) that portion of the Executive's Annual Base Salary earned but not previously paid through the Date of Termination; (ii) reimbursement of expenses incurred on or before the Date of Termination in accordance with Section 3.7, above; and (iii) any accrued vacation pay, in each case to the extent not theretofore paid (the sum of the amounts described in clauses (i), (ii), and (iii) shall be hereinafter referred to as the "Accrued Obligations").  The Accrued Obligations shall be paid on the regular payday following the Date of Termination.  

		
	(b)
	Subject to Executive’s full compliance with Executive’s obligations pursuant to this Agreement, including but not limited to Sections 4.6, 5.3, 6 and Schedule A, the Company shall pay, or cause to be paid, to the Executive: 

		
	i.
	An amount equal to the aggregate of twelve (12) months of the Executive's Annual Base Salary, which amount is not wages for labor performed and may be withheld for any prior breach or breach during the period of such payments by Executive of his obligations in this Agreement or any applicable confidentiality, inventions assignment and return of property or similar undertaking;   

		
	ii.
	An amount, which shall be determined in the sole discretion of the Compensation Committee exercising good faith and paid at the same time as the Company pays its incentives to management generally under the applicable plan, for the performance incentive set forth in Section 3.2 above for the annual performance period fully completed prior to the Date of Termination. For the avoidance of doubt, such incentive shall not be paid pro rata 

for a performance period that is not fully complete prior to the Date of Termination and shall be in accordance with the terms of the applicable incentive plan in effect at the time of termination.

Such amount in b(i) above shall be paid in twelve (12) and six (6) equal monthly installments, respectively, payable as of the first day of the month beginning within sixty (60) days after the Date of Termination or any later date set forth below; provided, however, if the sixty (60) day period spans two (2) calendar years, the said payments shall commence in the second calendar year.  Installments shall be made during the “short-term deferral period” following the termination of employment, as such term is defined in Section 409A of the Internal Revenue Code (the “Code”).  At the conclusion of this short-term deferral period, the installment payments shall continue to the extent that the Executive’s  remaining severance payment does not exceed two times the lesser of (i) the executive’s annual compensation or (ii) the compensation limit in effect under Section 401(a)(17) of the Code for the calendar year including the date of termination (the “Two Times Limit”); provided, however, to the extent the remaining severance payments exceed the Two Times Limit, then the installment payments which are below the Two Times Limit shall be paid to the Executive.  Any remaining severance payments which exceed the Two Times Limit shall continue to paid in installments unless (i) the Executive is a “specified employee” as defined in Section 409A of the Code at the time of his termination of employment with the Company and (ii) the deferral of further payments payable hereunder as a result of such termination of employment is necessary in order to prevent any accelerated or additional tax under Section 409A of the Code, in which case,  the Company will defer the commencement of the payment of any such payments (without any reduction in such payments ultimately paid to the Executive) until the date that is six months following his termination of employment with the Company (or the earliest date as is permitted under Section 409A of the Code). If the Executive dies during such six (6) month period, then payments shall commence within thirty (30) days after the Executive's death).  All payments to be made upon a termination of employment under this agreement may only be made upon a “separation from service” within the meaning of such term under Section 409A of the Code.

		
	(c)
	To the extent not theretofore paid or provided, the Company (or Patheon, as the case may be) shall pay or provide, or cause to be paid or provided, to the Executive any other amounts or benefits required to be paid or provided or which the Executive is eligible to receive under any plan, program, policy or practice or contract or agreement of the Patheon Group (such other amounts and benefits shall be hereinafter referred to as the "Other Benefits"), in accordance with the terms and normal procedures of each such plan, program, policy or practice or contract or agreement, based on earned, accrued or vested benefits through the Date of Termination.

If the Executive receives payments and benefits pursuant to this Section 5.1, then the Executive shall not be entitled to any other severance pay or benefits under any severance plan, program or policy of any member of the Patheon Group, unless otherwise specifically provided therein in a specific reference to this Agreement;  provided, however, in the event any payment is made, or required to be made, under any such severance plan, program or policy, then the amounts payable under this Section 5.1 shall be reduced by such amount.  

5.2    Death or Disability; Cause; Other than for Good Reason  

If the Executive's employment is terminated due to death, Disability or for Cause, or if the Executive voluntarily terminates his employment without Good Reason or for retirement, this Agreement shall terminate without further obligations to the Executive other than the obligation to pay to the Executive his Accrued Obligations through the Date of Termination and the Other Benefits earned, accrued, or vested through the Date of Termination, in each case to the extent not theretofore paid or provided.  All Accrued Obligations shall be paid to the Executive in accordance with Section 5.1(a) and the Other Benefits shall be paid to the Executive in accordance with Section 5.1(c).  The Company (and the Patheon Group) will have no further obligation to pay any compensation of any kind (including, without limitation, any bonus or portion of a bonus that otherwise may have become due and payable to the Executive with respect to the year in which such Date of Termination occurs), or severance payment of any kind, nor will the Company (or the Patheon Group) have any obligation to make any payment in lieu of notice.

5.3    Release  

Notwithstanding anything contained herein to the contrary, the Company shall only be obligated to make the payments under Section 5.1(b) if, in addition to the other contingencies under Section 5.1(b):  (a) within the 21-day period after the Date of Termination, the Executive executes a general release, in a form provided by the Company, of all current or future claims, known or unknown, against the Patheon Group, its officers, directors, shareholders, limited partners, members, employees and agents arising on or before the date of the release, including but not limited to all claims arising out of the Executive's employment with the Patheon Group or the termination of such employment, and (b) the Executive does not negotiate substantially the terms of the release or revoke the release during the seven-day revocation period prescribed by the Age Discrimination in Employment Act of 1967, as amended, or any similar revocation period, if applicable.  The Company shall be obligated to provide the release to the Executive promptly following the Date of Termination.  

ARTICLE 6
RESTRICTIVE COVENANTS

6.1    In General  

		
	(a)
	The Executive acknowledges and agrees that the Patheon Group is a business engaged in the sale of commercial pharmaceutical manufacturing capabilities and/or pharmaceutical development services, and during the Executive’s employment, the Patheon Group’s business may expand or change (“the Patheon Group’s Business”).  Any such expansions and changes shall expand or change the Executive’s obligations under this Agreement accordingly.  The Patheon Group’s Business is international in scope and without geographical limitation and the Patheon Group has valuable business relationships within its industry throughout the world.  

		
	  (b)
	By virtue of the Executive’s employment by and position with the Company: (i) the Executive has or will have access to confidential and proprietary information of the Patheon Group, including valuable information about its business operations and methods and the persons with whom it does business in various locations throughout the world that is not generally known to, or readily ascertainable by, the Patheon Group’s competitors, and the Executive understands that the continued success of the Patheon Group depends upon the use and protection of a large body of confidential and proprietary information, and (ii) the Executive has specialized knowledge of, and has received or will receive specialized training in, the Patheon Group’s Business.

		
	(c)
	The Executive authorizes the Company to disclose this Agreement to Executive’s future or prospective employers along with notification of the Company’s intent to exercise all rights it has to seek enforcement of its terms.

    
6.2    Confidentiality Undertaking
The Executive confirms that he is bound by the provisions of the Confidentiality Undertaking covenant set out in Schedule A hereto.

6.3    Non-Compete, Non-Solicitation 

		
	(a) 
	Executive agrees that for one (1) year after the termination of the Executive’s employment with the Company by the Executive or the Company for any reason whatsoever (the "Non-compete Period"), the Executive shall not directly or indirectly engage in any of the following activities (except in connection with his/her duties for the Company):

		
	(i) 
	engage in any Competitive Business as defined in this Agreement   within the geographical areas set forth in Section 6.3(b);

		
	(ii)  
	within the geographical areas set forth in Section 6.3(b), solicit or do business which is the same, similar to or otherwise in competition with the business engaged in by the Patheon Group, from or with persons or entities: (a) who are customers of the Patheon Group; (b) whom Executive or someone for whom Executive was responsible solicited, negotiated, contracted, serviced or had contact with on the Patheon Group’s behalf; (c) who were customers of the Patheon Group at any time during the last year of the Executive’s employment with the Patheon Group; or (d) to whom the Patheon Group had made proposals to do business at any time during the last year of the Executive’s employment with the Company; or

		
	(iii)  
	offer employment to or otherwise solicit for employment any employee or other person who had been employed by the Patheon Group during the last year of the Executive’s employment with the Company and whom Executive knows, worked with supervised or has confidential information about; 

		
	(iv)
	within the geographical areas set forth in Section 6.3(b), be employed (or otherwise engaged) by a Competitive Business in (i) a management capacity, (ii) other capacity providing the same or similar services which the Executive provided to the Patheon Group, or (iii) any capacity connected with business activities competitive with the Patheon Group;

		
	(v)
	directly or indirectly take any action which is materially detrimental or otherwise intended to be adverse to the Patheon Group’s goodwill, name, business relations, prospects and operations.

		
	(b)
	The restrictions set forth in this Section 6.3 apply to the following geographical areas: (i) the Research Triangle Park, North Carolina metropolitan area; (ii) the Cincinnati, Ohio metropolitan area; (iii) the greater Boston, Massachusetts 

metropolitan area; (iv) any city, metropolitan area, county (or similar political subdivisions in foreign countries) in which the Patheon Group is located or does or, during the Executive’s employment with the Company, did business; and (v) any city, metropolitan area, county (or similar political subdivisions in foreign countries) in which the Executive’s services were provided, or for which the Executive had responsibility, or in which the Executive worked on Patheon Group projects, while employed by the Company.

		
	 (c)  
	If, at the time of enforcement of this Section 6.3, a court holds that the restrictions stated herein are unreasonable under circumstances then existing, the Executive agrees that they be “blue-penciled” or rewritten by the court to the extent necessary to render them enforceable.  In addition, the one (1) year time period specified in this Section 6.3 shall be tolled and shall not run during any time the Executive is in violation of Section 6.3 or period(s) of time required for legal action to enforce the provisions of this Section 6.3.

		
	(d) 
	“Competitive Business” means a business engaged in the sale of commercial pharmaceutical or biological manufacturing capabilities and/or the sale of pharmaceutical or biological development services.

 
6.4    Remedies  

Because the Executive has access to Confidential Information (as defined in Schedule A), the Executive understands and agrees the Patheon Group would suffer irreparable harm from a breach of this Agreement and that money damages would not be an adequate remedy for any such breach of this Agreement.  Therefore, in the event of a breach or threatened breach of this Agreement (including Schedule A), the Patheon Group and its successors or assigns, in addition to other rights and remedies existing in their favor, shall be entitled to specific performance and/or injunctive or other equitable relief from a court of competent jurisdiction in order to enforce, or prevent any violations of, the provisions hereof (without posting a bond or other security) as well as court costs and reasonable attorney’s fees.   

6.5    Acknowledgements

The Executive agrees and acknowledges that the promises and obligations made by the Company in this Agreement (specifically including, but not limited to, the payments and benefits provided for under Section 5.1(b) and (d) hereof) constitute sufficient consideration for the covenants contained in this Article 6 and Schedule A.  The Executive further acknowledges that it is not the Patheon Group's intention to interfere in any way with his employment opportunities, except in such situations where the same conflict with the legitimate business interests of the Patheon Group.  The Executive agrees that he will notify the Company in writing if he has, or reasonably should have, any questions regarding the applicability of this Article 6 and Schedule A.  

6.6    Survival   

Subject to any limits on applicability contained therein, this Article 6 and Schedule A shall survive and continue in full force in accordance with their respective terms notwithstanding any expiration or termination of this Agreement.

ARTICLE 7
GENERAL PROVISIONS

7.1    Entire Agreement

This Agreement, together with Schedule A attached hereto and incorporated herein by reference, when executed by both parties shall constitute the entire agreement pertaining to the Executive’s employment and supersedes all prior agreements, understandings, negotiations and discussions, whether written or oral, pertaining to the Executive’s employment, and there are no representations, undertakings or agreements of any kind between the parties respecting the subject matter hereof except those contained herein. For the avoidance of doubt, the parties agree that the Prior Employment Agreement is amended and restated in its entirety on the terms and conditions set forth in this Agreement.  The recitals set forth above are incorporated herein by this reference with the same force and effect as if set forth herein as agreements of the parties. 

7.2    Severability

If any provision of this Agreement is declared void or unenforceable, such provision shall be deemed severed from this Agreement to the extent of the particular circumstances giving rise to such declaration and such provision as it applies to other persons and circumstances and the remaining terms and conditions of this Agreement shall remain in full force and effect. 

7.3    Representations
The Executive represents and warrants that (a) he or she is not a party to any contract, understanding, agreement or policy, whether or not written, with his current employer (or any previous employer) or otherwise, that would be breached by the Executive's entering into, or performing services under, this Agreement and (b) will not knowingly use any trade secret, confidential information, or other intellectual property right of any other party in the performance of his duties hereunder.  The Executive will indemnify, defend, and hold each member of the Patheon Group harmless, from any and all suits and claims arising out of any breach of such restrictive contracts, understandings, agreements or policies.
		
	7.4
	Notices

All notices and other communications hereunder shall be in writing and shall be given by hand delivery to the other party or by registered or certified mail, return receipt requested (a return receipt shall be deemed acceptance), postage prepaid, addressed as follows:

If to the Executive:

Francisco Negron
2 Southwind Drive
Flanders, NJ 07836

If to the Company:

James Mullen
111 Speen Street, Suite 550
Framingham, MA  01701
Attention: Chief Executive Officer

With a copies to:

Rebecca Holland New
4721 Emperor Blvd, Suite 200
Durham, NC 27703
Attention: Senior Human Resources Executive

and

Eric Sherbet
111 Speen Street, Suite 550
Framingham, MA  01701
Attention: General Counsel

or to such other address as either party shall have furnished to the other in writing in accordance herewith.  Notice and communications shall be effective when actually received by the addressee.

7.5    Withholding

The Company may withhold from any wages or other compensation and benefits payable under this Agreement all federal, state, city and other taxes or amounts as shall be determined by the Company to be required to be withheld pursuant to applicable laws, or governmental regulations or rulings. The Executive shall be solely responsible for the satisfaction of any taxes (including employment taxes) imposed on employees and penalty taxes on nonqualified deferred compensation.

7.6    Waiver

The Executive's or the Company's failure to insist upon strict compliance with any provision of this Agreement or the failure to assert any right the Executive or the Company may have hereunder, including, without limitation, the right of the Executive to terminate employment for Good Reason, shall not be deemed to be a waiver of such provision or right or any other provision or right of this Agreement.

7.7    Successors

		
	(a)
	This Agreement is personal to the Executive and is not assignable by the Executive.  This Agreement shall inure to the benefit of and be enforceable by the Executive's legal representatives.  This Agreement shall inure to the benefit of and be binding upon the Company, the other members of the Patheon Group, and their respective successors and assigns.  

		
	(b)
	The Company, at its discretion, may assign this Agreement, and will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of Patheon or the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place. 

7.8    Section 409A of the Code

		
	(a)
	Although the payments and benefits provided under this Agreement are intended to be exempt from the application of, or, to the extent subject thereto, comply with, the requirements of Section 409A of the Code (“Section 409A”), the tax treatment of the payments and benefits provided under this Agreement is not warranted or guaranteed. Specifically, any taxable benefits or payments provided under this Agreement are intended to be separate payments that qualify for the “short-term deferral” exception to Section 409A to the maximum extent possible, and to the extent they do not so qualify, are intended to qualify for the involuntary separation pay exceptions to Section 409A to the maximum extent possible.  This Agreement shall be construed, administered, and governed in a manner that effects such intent.  Without limiting the foregoing, the payments and benefits provided under this Agreement may not be deferred, accelerated, extended, paid out or modified in a manner that would result in the imposition of an additional tax under Section 409A upon the Executive.  

		
	(b)
	Each amount to be paid or benefit to be provided under this Agreement shall be construed as a separate identified payment for purposes of Section 409A.  To the extent required by Section 409A, each reimbursement or in-kind benefit provided under this Agreement that will not be excluded from Executive's income when received is subject to the following requirements: (i) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during each calendar year cannot affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year; (ii) any reimbursement of an eligible expense shall be made on or before the last day of the calendar year following the calendar year in which the expense was incurred; and (iii) the right to reimbursements or in-kind benefits under this Agreement shall not be subject to liquidation or exchange for another benefit.  

		
	(c)
	Although the Company will endeavor to avoid the imposition of taxation, interest and penalties under Section 409A, the tax treatment of the benefits provided under this Agreement is not warranted or guaranteed.  Neither the Patheon Group nor its directors, officers, employees or advisers shall be held liable for any taxes, interest, penalties or other monetary amounts owed by the Executive or other taxpayer as a result of the Agreement.  Any reference in this Agreement to Section 409A will also include any proposed, temporary or final regulations, or any other guidance, promulgated with respect to such Section 409A by the U.S. Department of Treasury or the Internal Revenue Service.

7.9    Governing Law.  

This Agreement shall be construed and interpreted in accordance with the substantive laws of the State of Massachusetts, without giving effect to any choice or conflict of law provision or rule (whether of the State of Massachusetts or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the State of Massachusetts. The state and federal courts located in Massachusetts shall be the exclusive forum for the adjudication of all disputes between the parties arising out of or relating to this Agreement.  Each of the parties hereby irrevocably consents to the personal jurisdiction of the federal and state courts in the State of Massachusetts with respect to any matters arising out of this Agreement and waives any and all objections and defenses to such personal jurisdiction regardless of whether such objection or defense is based upon the venue, Massachusetts’ long-arm statute, residence and/or contacts with Massachusetts, the convenience of the witnesses and/or parties, the inconvenience of the forum, or otherwise.

NOW THEREFORE, the parties below have entered into this Agreement as of the date first written above.

Patheon Pharmaceutical Services Inc. 

By:   __/s/ Rebecca Holland New_____
    
Name:  _Rebecca Holland New______

Title: ___CHRO___________________

      EXECUTIVE 
SIGNED, SEALED AND DELIVERED    )
in the presence of            )
/s/ Kelli Daniel            )      /s/ Francisco Negron            
Name of Witness: Kelli Daniel        )    Francisco Negron

SCHEDULE A
TO
AMENDED AND RESTATED EMPLOYMENT AGREEMENT
 WITH
Francisco Negron

CONFIDENTIALITY, INVENTIONS ASSIGNMENT AND RETURN OF PROPERTY UNDERTAKING 

In consideration of Franco Negron (the "Executive") accepting an amended and restated employment agreement between the Executive and Patheon Pharmaceutical Services Inc. (the “Company”) dated ____________, 2015 (the "Agreement") to which this Confidentiality, Inventions Assignment and Return of Property Undertaking (“Confidentiality Undertaking”) is attached as Schedule A, the Executive undertakes and covenants with the Patheon Group (as defined in the Agreement) as follows:

		
	1.
	CONFIDENTIAL INFORMATION

Executive acknowledges that all Confidential Information (defined below) is the sole and exclusive property of the Patheon Group (or a third party providing such information to the Patheon Group).  At all times during Executive’s employment and thereafter, Executive will hold in strictest confidence and will not use, disclose, copy or remove from the Patheon Group premises any Confidential Information, nor aid third parties in obtaining or using any Confidential Information, nor access or attempt to access any Patheon Group computer systems, networks or any resources or data that resides thereon, except as such use, disclosure, copying, removal or access may be required in connection with Executive’s employment and only then in accordance with applicable Patheon Group policies and procedures and solely for the Patheon Group’s benefit.  Executive further acknowledges that the applicable Patheon Group policies and procedures referenced in the preceding sentence include but are not limited to the following and apply regardless of whether or not the information is Confidential Information:  (i)  no forwarding of electronic files, data, emails or other information to home, personal or external email accounts even for the purpose of working remotely; (ii) no use of thumb drives, flash drives or other portable devices or copying methods without the express written consent of the Company; (iii) no copying of hard copy documents for removal from the worksite even for the purpose of working remotely; (iv) emails, voicemails or other communications, whether written, verbal, electronic or otherwise, sent to Executive are for his/her eyes/ears only and are not to be shared with any other employee or person, except with the express consent of the sender; and (v) violation of policies and procedures regarding Patheon Group information is grounds for immediate termination for Cause.  Additionally, Executive will notify the Patheon Group of any known or suspected unauthorized use, disclosure, copying or removal of Confidential Information by others.  

As used in this Agreement, “Confidential Information” means any and all facts, data or information of the Patheon Group (or of third parties providing such information to the Patheon Group) that is not known by, or generally available to the public at large, that concerns the business of the Patheon Group (or third parties providing such information to the Patheon Group) whether now existing or to be developed in the future,  and whether embodied in tangible or intangible form or merely remembered, including but not limited to trade secrets or other intellectual property; products, product plans, designs, ideas, concepts, costs, methods or policies; prices or price formulas; processes; procedures; raw materials; research, development or know-how; customer lists and information, information relating to customers, prospective partners, partners, parents, subsidiaries, affiliates and other entities; financial information; computer software (including design, programming techniques, flow charts, source code, object code, and related information and documentation); products and services; inventory lists; market and/or product research and development data; business strategies and methodologies, strategic or business plans, training manuals and methodologies; employee phone and address lists, personnel data, incentive packages, compensation data and employee performance data; and all other information of any kind or character relating to the development, improvement, manufacture, sale, or delivery of products or services by the Patheon Group.

If Executive is required to disclose Confidential Information pursuant to a court order or such disclosure is necessary to comply with applicable law or defend against claims, Executive shall: (i) notify the Company promptly before any such disclosure is made; (ii) at the Company's request and expense take all reasonably necessary steps to defend against such disclosure, including defending against the enforcement of the court order, other government process or claims; and (iii) permit the Patheon Group to participate with counsel of its choice in any related proceeding.

2.    INVENTIONS

		
	a.
	Inventions.  Subject to paragraph 2 b., Executive agrees that all right, title, and interest in and to (i) all discoveries, designs, ideas, works of authorship, and inventions created, conceived, reduced to practice, or otherwise developed, in whole or 

in part, by Executive, whether jointly or individually, during Executive’s employment or within three years following termination of employment for any reason whatsoever; (ii) all improvements, modifications, and derivative works to and of any of the foregoing in (i); and (iii) all patent, copyright, trademark, trade secret and other intellectual property rights in any of the foregoing in (i) and (ii) (all the foregoing in (i)-(iii), collectively, the "Inventions") will be owned solely and exclusively by the Company.  Without limiting the foregoing, all copyrightable subject matter included in the Inventions shall constitute “work made for hire” under applicable copyright law.  Executive will:

		
	(i)
	promptly and fully disclose and describe, in detail satisfactory to the Company, all such Inventions in writing to the Company;

		
	(ii)
	irrevocably and unconditionally assign, and Executive does hereby irrevocably and unconditionally assign, to the Company, without further compensation or other consideration, any and all of Executive’s rights, title and interest in and to the Inventions, including without limitation (1) all rights to collect royalties for any use, and pursue remedies for any infringement, misappropriation, or other violation, thereof and (2) all applications for letters of patent, copyright registrations, trademark, service mark, and trade dress registrations, and  industrial design or other forms of protection granted for the Inventions throughout the world;

		
	(iii)
	deliver promptly to the Company, upon request and in the form and manner prescribed by the Company (without charge to the Company but at the Company's expense), including without limitation Executive’s notarized signature in execution of, the written instruments described in paragraph b. and perform all other acts deemed necessary by the Company to obtain and maintain the instruments and to transfer all rights and title thereto to the Company in accordance with this Agreement; and

		
	(iv)
	promptly render all assistance that may be required by the Company to enable it to protect or exploit the Inventions in any country of the world.

In addition, Executive does hereby waive and agree never to assert any rights in the Inventions, and any part or parts thereof, that are not susceptible of assignment by Executive under applicable law, including, but not limited to, any moral rights or the right to the integrity or attribution of the Inventions, or any other right to be associated with the Inventions as its author, inventor, or user by name or under a pseudonym or the right to remain anonymous.

		
	b.
	Excluded Inventions.      The provisions of paragraph 2 a. will not apply to Inventions which fulfill all of the following criteria:

		
	(i)
	Inventions for which no equipment, supplies, facility or Confidential Information belonging to the Company were used; and

		
	(ii)
	Inventions that do not relate to the business of the Company or to the Company's actual or demonstrably anticipated processes, research or development; and

		
	(iii)
	Inventions that do not result from any work performed by Executive for the Company.

3.    RETURN OF COMPANY PROPERTY

Upon the Company’s request and, in any event, upon the cessation of Executive’s employment with the Company, Executive will return to the Company all Confidential Information in Executive’s possession or control, along with all Company property, including but not limited to keys, pass cards, identification cards, computer hardware and software, manuals, passwords, customer lists, sales records, business plans, any data concerning customers of the Company, brochures of the Company and of any competitor, all corporate records, policy handbooks, receipts, documents, records, files and other documents in whatever form they exist, whether electronic, hard copy or otherwise, and all copies, notes or summaries thereof.  Any and all such documents contained on Executive’s personal computer or devices shall be printed, delivered to the Company and thereafter deleted from the personal computer/device.  These documents and items must be returned whether in Executive’s possession, work area, home, vehicle or in the wrongful possession of any third party with Executive’s knowledge or acquiescence, and whether prepared by the Company or any other person or entity.

I HAVE READ THIS AGREEMENT CAREFULLY AND UNDERSTAND ITS TERMS.

	
		
	

/s/ Francisco R. Negron  (SEAL)
Executive’s Signature

Francisco R. Negron 
Print Executive Name

The signature above was witnessed by:

/s/ Rebecca Holland New  
Witness’ Signature

R.H. New
Witness’ Name
	

26-Oct-2015 
Date:

26 Oct 2015 
Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]